Silver Lake Partners IV and its affiliates sold approximately $29.5 million worth of Dell Technologies (NASDAQ:DELL) Class C Common Stock on September 9, 2026, at prices ranging from $533.7 to $550.71 per share. The sale occurred while Dell's stock was trading near its 52-week high, having gained 358% over the past year, and is considered overvalued by InvestingPro analysis. This divestment follows several positive analyst updates for Dell, citing strong AI momentum and infrastructure refresh as key growth drivers.

US spot Bitcoin ETFs experienced a significant rebound on July 2, recording $221.7 million in net inflows, breaking a 10-day outflow streak. Fidelity's FBTC led this recovery with $166 million in inflows, while BlackRock's IBIT continued its streak of outflows. This shift suggests a maturing market where investors are becoming more selective across different ETF issuers.

Structure Therapeutics (GPCR) reported a 3.3% mean body-weight reduction with a single dose of ACCG-2671 in a Phase 1/2a trial. The company is now testing daily and weekly regimens in an 84-day study, with results expected in the first half of 2027, to determine if sustained efficacy and tolerability can be achieved with repeat dosing. The primary concern is managing gastrointestinal side effects while maintaining the weight-loss signal, as the initial results showed significant adverse events even at lower doses.

Hayward Holdings Inc. (HAYW) stock has dropped to a new 52-week low of $12.92, representing a 19.18% decrease over the past year. Despite this downturn, InvestingPro data suggests the stock may be undervalued, boasting a perfect Piotroski Score of 9 and a P/E ratio of 18.43. The company recently surpassed Q2 2026 earnings expectations, and analysts like Stifel maintain a "Buy" rating, indicating a potential rebound.

Palo Alto Networks CEO Nikesh Arora estimates that AI is driving a need to modernize approximately $1 trillion of outdated cybersecurity infrastructure. The company reported strong fiscal fourth-quarter results, with revenue up 34% and next-generation security annual recurring revenue up 63%. While this presents a significant opportunity for Palo Alto, the company faces challenges including the time it will take for spending to materialize and intense competition in the cybersecurity market.

Akash J. Palkhiwala, EVP, CFO, and COO of QUALCOMM INC/DE (NASDAQ:QCOM), sold 2,500 shares of company stock for approximately $457,129 on September 11, 2026. These transactions were made under a Rule 10b5-1 trading plan adopted in December 2025. The article also notes Qualcomm's recent partnership with Amazon for AI inference and optical connectivity, which has garnered positive analyst attention.

Mark Brosius, EVP at Intuitive Surgical Inc. (NASDAQ:ISRG), sold $17,140 worth of company stock through two transactions last week under a pre-arranged trading plan. Despite the stock being down 34.8% year-to-date, InvestingPro analysis suggests ISRG is undervalued, and the company recently reported strong second-quarter sales and earnings, leading to several analyst upgrades and positive outlooks.

Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences Corp, sold 619 shares of company stock worth $54,168 at $87.51 per share on September 11, 2026. Concurrently, he acquired 619 shares through employee stock options at an exercise price of $72.68 per share. These transactions, conducted under a Rule 10b5-1 trading plan, leave Mr. Lippis with over 40,000 shares, and occurred while the stock was trading below the sale price, though InvestingPro analysis suggests fair valuation.

Talon Private Wealth LLC acquired 7,741 shares of Merck & Co., Inc. (NYSE:MRK) valued at approximately $995,000 during the second quarter, bringing institutional ownership in Merck to 76.07%. Merck exceeded earnings and revenue expectations, reporting $16.61 billion in revenue, and declared a quarterly dividend of $0.85 per share. Despite a "Moderate Buy" consensus from analysts, concerns remain regarding Merck's valuation and the need to offset potential revenue loss from Keytruda's 2028 patent expiration.

Morgan Stanley has initiated coverage of Coinbase Global (Nasdaq: COIN) with an "Equal Weight" rating and a $250 price target, marking its first call on the crypto exchange. The bank highlights Coinbase's expansion beyond spot crypto trading into a broader financial infrastructure, including equities, commodities, and tokenized assets, which significantly increases its addressable market. This strategic diversification, evident in Coinbase's recent product rollouts and financial results, positions the company for convergence between crypto and traditional finance.